LBrHM1
Novel lumbricin-family antimicrobial peptide from Hirudo medicinalis (Serebrennikova 2025) — N-terminal fragment is unique among known AMPs; active against Bacillus subtilis.
- Hementerin80 kDa
- Hementin80 kDa
- Hementin-Like Protein (HLP-1)80 kDa
- Leech Collagenase70 kDa
- Haemadipsa yanyuanensis Progranulin (Hy-PGRN)70 kDa
- Leech Apyrase67 kDa
- Calin65 kDa
- Hyaluronidase60 kDa
- Antithrombin III binding protein58 kDa
- Collagenolytic Fibrinolysin55 kDa
- Leech Thrombospondin-Like Protein50 kDa
- LBrHM16.5 kDa
Mechanistic Evidence Box
Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.- Page type
- Compound profile
- Evidence type
- Preclinical / biochemical characterization
- Evidence level
- In vitro
- Drug vs leech
- Recombinant (genetically expressed)
- Safety domains
- Antibiotic stewardship
Clinical translation limit
LBrHM1's in vitro antibacterial activity does NOT establish clinical efficacy. No FDA-approved derivative exists; activity demonstrated only against laboratory test strains.
Molecular Profile
- Category
- Antimicrobial
- Evidence tier
- Preclinical
- Molecular weight
- 6,500 Da
- Source species
- Hirudo medicinalis
- Discovered
- 2025 · Serebrennikova M et al.
Biological Targets
- → Bacillus subtilis (in liquid medium)
Key Citations
- Serebrennikova M et al. (2025), Int J Mol Sci · PMID 40725149
External Resources
Related Antimicrobial Compounds
Theromacin
Cationic, cysteine-rich antimicrobial peptide (75 amino acids) active against Gram-positive bacteria — part of the leech's innate immunity.
Theromyzin
Linear anionic antimicrobial peptide (86 amino acids) active against Gram-positive bacteria — the first anionic antimicrobial peptide described in invertebrates.
Macrostomin
Antimicrobial peptide active against Gram-positive bacteria — amphipathic alpha-helix.
Hirunipins
Newly-characterized antimicrobial peptide family (Kumar 2025) — candidate next-generation antibiotics against AMR pathogens.